Project Details
| Short title | MK-2870-032 |
|---|---|
| Acronym | TROFUSE-032 |
| Status | Active |
| Effective start/end date | 11/11/25 → 11/11/30 |
CTU: A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
- Sabanathan, Dhanusha (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Quinlan, Gabriel (Clinical Trial Unit Staff)
- Martin, Lewis (Clinical Trial Unit Staff)
- Garcia, Michelle (Clinical Trial Unit Staff)
- Armstrong, Emilia (Clinical Trial Unit Staff)
- Delahunt Smoleniec, Jacqui (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
- Lawrie, Angus (Clinical Trial Unit Staff)
Project: Research